Welcome to our dedicated page for Utah Med Prods news (Ticker: UTMD), a resource for investors and traders seeking the latest updates and insights on Utah Med Prods stock.
Utah Medical Products Inc. develops, manufactures and markets disposable and reusable specialty medical devices, with a stated focus on health care for women and babies. Its products are used in areas such as blood pressure monitoring, blood collection, electrosurgery, gynecology, neonatal critical care, perinatology and urology, serving hospitals, outpatient clinics and physicians' offices.
Company updates commonly cover quarterly and annual financial performance, domestic and outside-U.S. sales trends, foreign-currency effects, product-category demand, OEM and distributor relationships, and profit margins. Recurring corporate actions include quarterly cash dividends, open-market share repurchases when disclosed, board appointments and other governance updates for the Nasdaq-listed common stock.
Utah Medical Products (Nasdaq: UTMD) announced a quarterly cash dividend of $0.31 per share, payable on July 3, 2026 to shareholders of record at the close of business on June 17, 2026. This reflects a 1.6% increase versus the same quarter last year.
The company develops and sells disposable and reusable specialty medical devices focused on maternal and neonatal care in over 100 countries. For more information, visit UTMD's website.
Utah Medical Products (Nasdaq: UTMD) reported 1Q 2026 results: consolidated sales declined 10.2% versus 1Q 2025, GP fell 4.6% to $5,282, OI fell 18.7% to $2,565 (29.4% margin), NI fell 14.4% to $2,604, and EPS was $0.818 (down 11.0%). Cash equivalents were $4.1M higher than March 31, 2025. The company cited lost 1Q 2026 sales to a former China distributor and PendoTECH as principal drivers of lower revenue.
Utah Medical Products (Nasdaq:UTMD) announced a quarterly cash dividend of $0.31 per share, payable April 3, 2026 to shareholders of record at the close of business March 17, 2026. This represents a 1.6% increase versus the same quarter a year earlier.
The company develops and markets specialty disposable and reusable medical devices focused on women and babies and distributes products in over 100 countries. Contact: Brian Koopman, (801) 566-1200.
Utah Medical Products (NYSE:UTMD) reported 2025 results with consolidated revenues of $38.5M, down 5.8% from 2024, and net income down 19%. EPS declined 12%. The company increased year-end cash to $85.8M after $8.4M in share repurchases and $4.0M in dividends.
Major drivers: loss of PendoTECH OEM sales, weaker OUS Filshie device sales, favorable FX partially offset declines, and continued strong gross margins despite higher input and personnel costs.
Utah Medical Products (Nasdaq: UTMD) appointed Kevin C. Timken, Esq. to its Board of Directors and approved a quarterly cash dividend of $0.31 per share.
Mr. Timken served as the company’s outside legal counsel for over 20 years and holds a J.D. from the University of Utah College of Law (1997). The dividend is payable on January 5, 2026 to shareholders of record at the close of business on December 16, 2025, representing a 1.6% increase versus the prior regular quarterly dividend.
Utah Medical Products develops and markets disposable and reusable specialty medical devices focused on women and babies and sells in over 100 countries. More information is available at www.utahmed.com.
Utah Medical Products (NASDAQ:UTMD) reported 3Q and 9M 2025 results impacted by global trade disruptions and FX movements. Total WW sales fell 1.9% (3Q) and 7.2% (9M) vs prior-year periods; constant-currency sales were modestly helped by FX (+$114 in 3Q, +$244 in 9M). Gross profit margin narrowed (3Q: 57.1% vs 58.0% prior) and operating income margin declined (3Q: 26.6% vs 33.4% prior) partly due to a $395 bad-debt reserve tied to an OUS distributor cancellation and higher operating expenses. Litigation and UK amortization continue to affect G&A. Balance sheet strengthened with higher current ratio, lower liabilities, higher equity, $3,006 paid in dividends and $7,361 used for share repurchases through 9M 2025.
Utah Medical Products (NASDAQ:UTMD) has announced a quarterly cash dividend of $0.305 per share of common stock. The dividend will be payable on October 2, 2025, to stockholders of record at the close of business on September 17, 2025.
This represents a 1.7% increase compared to the dividend declared in the same quarter of the previous year. The company specializes in healthcare products for women and their babies, manufacturing specialty medical devices used by clinicians globally.
Utah Medical Products (NASDAQ:UTMD) reported Q2 2025 financial results with consolidated revenues of $9.95 million, down 4.3% from Q2 2024. First half 2025 revenues decreased 9.6% to $19.66 million. The decline was primarily attributed to reduced sales to PendoTECH, representing 71% of Q2 decline and 86% of 1H decline.
Key metrics include Q2 2025 gross profit margin of 56.2% (vs 60.1% in Q2 2024), operating income margin of 32.1% (vs 33.1%), and net income margin of 30.6% (vs 33.2%). The company maintained a strong balance sheet with $82.2 million in cash and investments as of June 30, 2025, with no debt.
During 1H 2025, UTMD paid $2.0 million in dividends and repurchased $6.7 million of common stock while investing $0.2 million in capital expenditures.
Utah Medical Products (NASDAQ: UTMD) has announced a quarterly cash dividend of $0.305 per share of common stock. The dividend will be payable on July 3, 2025, to stockholders of record at the close of business on June 16, 2025. This represents a 1.7% increase compared to the dividend declared in the same quarter of the previous year. UTMD specializes in healthcare products for women and their babies, manufacturing and marketing specialty medical devices that are recognized globally across over 100 countries.
Utah Medical Products reported its Q1 2025 financial results, showing declines across key metrics compared to Q1 2024. The company experienced a 14.4% decrease in revenues, with sales dropping primarily due to reduced OEM sales to PendoTECH, which accounted for 91% of the decline.
Key financial metrics show:
- Gross Profit declined 18.1%
- Operating Income decreased 18.8%
- Net Income fell 23.1%
- Earnings Per Share reduced by 16.0%
Despite using $4.4 million in cash for share repurchases, dividends, and equipment purchases, the company maintained a strong balance sheet with $83.3 million in cash. Domestic sales excluding PendoTECH were 9% higher, while international sales were 14% lower in USD terms. The company's EBITDA for Q1 2025 was $4.65 million, supporting their year 2025 target of $18 million.